NeoCARD: A Response-Adapted Phase II Study of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients with Cardiomyopathy or Elevated Risk of Cardiotoxicity
- Sponsor:
- MUSC
- Sponsor Study ID:
- 104060
- CTO #:
- 104060
- NCT Number:
- NCT06845319
- Phase:
- II
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Breast
- Study Objectives:
- To determine the pathologic complete response (pCR) rate in TNBC patients treated with the 12-18 week CPP regimen. To evaluate radiologic response rate (RRR) at 12-week MRI defined by complete response and partial response.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Sivapiragasam, Abirami, at sivapira@musc.edu
- Study Coordinator, Madden, Avery, at maddenav@musc.edu
Trial opened at the following institutions:
Medical University of South Carolina